ArticleProceedings of the National Academy of Sciences of the United States of America2003
IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- Interleukin-18 in lupus nephritis: a meta-analysis of cytokine signaling dysregulation in immune-mediated nephropathy.Frontiers in immunology · 2025Pooled it
- Correlation between circulating interleukin-18 level and systemic lupus erythematosus: a meta-analysis.Scientific reports · 2021Pooled it
- The Roles of Interleukin-18 in Inflammation and Autoimmune Disease.Clinical reviews in allergy & immunology · 2026Review
- The advances of DEAD-box RNA helicase 17 in chronic non-infectious diseases.Frontiers in cardiovascular medicine · 2025Review
- Evaluation of causal associations between interleukin-18 levels and immune-mediated inflammatory diseases: a Mendelian randomization study.BMC medical genomics · 2023Article
- The role of inflammation in autoimmune disease: a therapeutic target.Frontiers in immunology · 2023Review
- The Role of Interleukin 18/Interleukin 18-Binding Protein in Adult-Onset Still's Disease and Systemic Juvenile Idiopathic Arthritis.Journal of clinical medicine · 2022Review
- Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment.Frontiers in immunology · 2022Review
- What Is IL-1 for? The Functions of Interleukin-1 Across Evolution.Frontiers in immunology · 2022Article
- DDX17 is an essential mediator of sterile NLRC4 inflammasome activation by retrotransposon RNAs.Science immunology · 2021Article
- Article
- Salivary Cytokines as Potential Diagnostic Biomarkers for Systemic Lupus Erythematosus Disease.Mediators of inflammation · 2021Review
- Interleukin-18 in Inflammatory Kidney Disease.Frontiers in medicine · 2021Review
- Procyanidin B2 prevents lupus nephritis development in mice by inhibiting NLRP3 inflammasome activation.Innate immunity · 2018Article
- IL-1 family cytokines and soluble receptors in systemic lupus erythematosus.Arthritis research & therapy · 2018Article
- Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus.Frontiers in immunology · 2018Article
- IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF-κB.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- IL-1 Vaccination Is Suitable for Treating Inflammatory Diseases.Frontiers in pharmacology · 2017Article
- Serum IL-18 as biomarker in predicting long-term renal outcome among pediatric-onset systemic lupus erythematosus patients.Medicine · 2016Article
- Correlation of plasma interleukin-18 concentration and severity of renal involvement and disease activity in systemic lupus erythematosus.Journal of nephropathology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
The lupus-like autoimmune syndrome of MRL/Mp-Tnfrsf6lpr (lpr) mice is characterized by progressive lymphadenopathy and autoantibody production, leading to early death from renal failure. Activation of T helper lymphocytes is one of the events in the pathogenesis of the disease in these mice and likely in human systemic lupus erythematosus. Among T helper lymphocyte-dependent cytokines, IFN-gamma plays a pivotal role in the abnormal cell activation and the fatal development of the lpr disease. IL-18, an inducer of IFN-gamma in T lymphocytes and natural killer cells, may contribute to the disease because cells from lpr mice are hypersensitive to IL-18 and express high levels of IL-18. To assess the contribution of IL-18 to the pathogenesis in the animal model, in vivo inhibition of IL-18 was attempted. Young lpr mice were vaccinated against autologous IL-18 by repeated administration of a cDNA coding for the murine IL-18 precursor. Vaccinated mice produced autoantibodies to murine IL-18 and exhibited a significant reduction in spontaneous lymphoproliferation and IFN-gamma production as well as less glomerulonephritis and renal damage. Moreover, mortality was significantly delayed in anti-IL-18-vaccinated mice. These studies support the concept that IL-18 plays a major role in the pathogenesis of the autoimmune syndrome of lpr mice and that a reduction in IL-18 activity could be a therapeutic strategy in autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.